InMode Ltd. (INMD)
INMD trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1742692/000117891326000377/0001178913-26-000377-index.htm. Net income: SEC 20-F (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | INMD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | Israel |
| IPO year | 2019 |
| SEC CIK | 0001742692 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $370.5M |
| Net income | $93.8M |
| Operating income | $85.4M |
| Net margin | 25.3% |
| Operating margin | 23.0% |
| Revenue growth | -6.2% |
| Cash | $302.5M |
| Total assets | $766.4M |
| P/E (computed) | 8.1× |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-10 |
| Cash and burn | $302.5M cash; operating cash flow $21.3M a quarter. | Report 2025-12-31 |
| Shares outstanding | 63,358,750 (2025-12-31); 69,558,670 a year earlier; 82,544,991 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-02-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $370.5M | $93.8M | $85.3M | $302.5M | No debt tags | $370.5M | 20-F 2026-02-10 |
| FY 2024 2024-12-31 | $394.8M | $181.3M | $132.7M | $155.3M | No debt tags | $394.8M | 20-F 2026-02-10 |
| FY 2023 2023-12-31 | $492.0M | $197.9M | $176.8M | $144.4M | No debt tags | $492.0M | 20-F 2026-02-10 |
| FY 2022 2022-12-31 | $454.3M | $161.5M | $181.6M | $97.5M | No debt tags | $454.3M | 20-F 2025-02-04 |
| FY 2021 2021-12-31 | $357.6M | $165.0M | $174.9M | $68.1M | No debt tags | $357.6M | 20-F 2024-02-13 |
| FY 2020 2020-12-31 | $206.1M | $75.0M | $79.2M | $68.9M | No debt tags | $206.1M | 20-F 2023-02-14 |
| FY 2019 2019-12-31 | $156.4M | $61.1M | $62.2M | $44.7M | No debt tags | $156.4M | 20-F 2022-02-10 |
| FY 2018 2018-12-31 | $100.2M | $22.4M | $36.9M | $24.7M | No debt tags | $100.2M | 20-F 2021-02-10 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2019-08-08 |
| Latest annual report | 20-F | 2026-02-10 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 157 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.5% |
| 1 month | -7.2% |
| 3 months | -12.7% |
| Year to date | -9.7% |
| 1 year | -7.2% |
| From 52-week high | -20.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| TMDX | TransMedics Group Inc. | $92.21 | +0.91% | $3.2B |
| AXGN | Axogen Inc. | $55.38 | -0.98% | $3.3B |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
| LIVN | LivaNova PLC | $92.44 | +1.23% | $5.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier